OCEAN Dx
OCEAN Dx provides a patented multiplexing molecular diagnostics kit that detects and identifies sepsis-causing pathogens directly from whole blood in under five hours, without the need for culture. The test covers 99% of sepsis pathogens—1,200 Gram positive and negative bacteria—with a limit of detection of 2 cells/mL from up to 9 mL of whole blood. The platform integrates Oxford Nanopore Technologies sequencing and has been clinically validated in a study with Bordeaux University Hospital.
- Healthcare Technology
- Biotechnology
- Medical Devices
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Sepsis affects 49 million people annually and carries a mortality rate of 35%, yet targeted antimicrobial therapy must begin within the first hours of suspicion. Traditional blood cultures take 1-10 days to deliver results, delaying appropriate treatment and contributing to poor outcomes and rising healthcare costs.
Solution
OCEAN Dx offers a patented multiplexing molecular diagnostics kit that detects and identifies sepsis-causing pathogens directly from whole blood without the need for culture. The test identifies 99% of sepsis pathogens—covering 1,200 Gram positive and Gram negative bacteria—in less than five hours, enabling clinicians to initiate targeted therapy in the critical early window. The platform achieves a limit of detection of 2 cells/mL from up to 9 mL of whole blood, delivering sensitivity that supports confident clinical decisions. By accelerating pathogen identification, the test aims to reduce the 35% mortality rate, improve antimicrobial stewardship, and lower healthcare costs associated with prolonged ICU stays and broad-spectrum antibiotic use.
Target Audience
Primary customers are hospital intensive care units, clinical microbiology laboratories, and emergency departments that need rapid sepsis diagnosis to guide immediate antimicrobial therapy in critically ill patients.
Features
- Patented multiplexing technology that identifies 1,200 Gram positive and Gram negative bacterial species covering 99% of sepsis-causing pathogens
- Limit of detection of 2 cells/mL directly from up to 9 mL of whole blood, eliminating the need for blood culture amplification
- Results in under 5 hours from sample collection, compared to 1-10 days for conventional blood cultures
- Direct-from-whole-blood workflow that removes the delay and contamination risks associated with culture-based methods
- Integration with Oxford Nanopore Technologies sequencing to accelerate pathogen detection and characterization
- Clinical performance validated in a study with Bordeaux University Hospital, matching the gold-standard reference method